CalciMedica Pivots to Pancreatitis Amid Financial, Clinical Hurdles

LA JOLLA, Calif. – March 03, 2026 – Clinical-stage biopharmaceutical company CalciMedica (Nasdaq: CALC) today presented a complex picture of progress and challenge, reporting year-end 2025 financials while navigating a significant clinical pipeline shift. The company confirmed its lead drug, Auxora™, was not responsible for toxicity concerns that halted a recent kidney disease trial, and simultaneously highlighted a clear and promising path forward for the drug in acute pancreatitis—a severe condition with no approved treatments.

This strategic pivot, coupled with encouraging preclinical data for a second drug candidate, underscores the potential of the company's novel anti-inflammatory platform. However, the announcements were tempered by a widening net loss and a cash runway projected to last only into the fourth quarter of 2026, placing a sharp focus on the financial tightrope the company must walk to bring its innovations to market.

Navigating a Clinical Setback

In January 2026, CalciMedica discontinued its Phase 2 KOURAGE trial, which was evaluating Auxora in patients with acute kidney injury (AKI) and associated respiratory failure. The decision followed a recommendation from the trial's Independent Data Monitoring Committee (IDMC) regarding a mortality imbalance between study groups, which warranted a reevaluation of the trial's design.

In its latest update, CalciMedica stressed that comprehensive internal and external reviews of the unblinded trial data found no evidence of drug-related toxicity. The company concluded that imbalances in the severity of patients' underlying illness at baseline may have contributed to the observed mortality difference. This finding is critical for the future of Auxora, as it absolves the drug itself of the safety concern, redirecting focus toward the complexities of trial design in critically ill populations. AKI is a notoriously difficult area for drug development, plagued by patient heterogeneity and high background mortality rates that can obscure a drug's true effect.

"First and foremost, in acute kidney injury, we and our external advisors have reviewed the unblinded KOURAGE data and have found no evidence of a drug-related toxicity," stated Rachel Leheny, Ph.D., Chief Executive Officer of CalciMedica. The company now plans to discuss the complete data set and potential future clinical pathways for AKI with the U.S. Food and Drug Administration (FDA) in the second quarter of this year.

Renewed Hope in Acute Pancreatitis

While the AKI program is being reassessed, CalciMedica is moving full-steam-ahead with Auxora in acute pancreatitis (AP), a painful and potentially lethal inflammatory condition that leads to approximately 300,000 hospitalizations in the U.S. annually. Currently, there are no FDA-approved drugs to treat AP, with patient care limited to supportive measures like IV fluids and pain management.

CalciMedica is preparing for what could be the first-ever pivotal program for an AP therapeutic in the United States. Following constructive discussions with the FDA, the company expects to finalize the design for this late-stage program in the first half of 2026. This progress is built on a foundation of highly encouraging results from its Phase 2b CARPO trial, the details of which were recently published in the peer-reviewed journal eClinicalMedicine, part of The Lancet Discovery Science suite.

The CARPO study showed that Auxora led to clinically meaningful, dose-dependent improvements across multiple endpoints. Most notably, patients receiving medium and high doses of Auxora experienced a statistically significant 100% reduction in new-onset severe respiratory failure—a frequent and deadly complication of severe AP—compared to placebo. The high-dose group also demonstrated a statistically significant improvement in a hierarchical composite endpoint that included mortality, organ failure, and time to discharge. These results, combined with a favorable safety profile, strongly position Auxora as a potential first-in-class therapy for a major unmet medical need.

A Novel Platform Targeting Inflammation

Underpinning CalciMedica's pipeline is its proprietary technology targeting calcium release-activated calcium (CRAC) channels. These channels are critical regulators of calcium influx into cells, particularly immune cells. In inflammatory diseases, overactive CRAC channels can lead to a massive immune response and subsequent tissue damage. By inhibiting these channels, CalciMedica's drugs aim to modulate the immune system and protect organs without the broad immunosuppression associated with some other anti-inflammatory agents.

The potential of this platform extends beyond pancreatitis. The company is also advancing a second CRAC channel inhibitor, CM5480, as a potential therapy for pulmonary arterial hypertension (PAH). Preclinical data published in JCI Insight demonstrated that CM5480 could mitigate pulmonary hypertension and its associated cardiac dysfunction in animal models. By targeting the abnormal proliferation of vascular cells and inflammation that drive PAH, CM5480 represents a differentiated, disease-modifying approach compared to existing PAH treatments that primarily focus on vasodilation. CalciMedica anticipates submitting an Investigational New Drug (IND) application to the FDA for CM5480 in 2027.

The Financial Balancing Act

Despite the clinical promise, CalciMedica faces significant financial headwinds. The company reported a net loss of $29.6 million for 2025, a substantial increase from the $13.7 million loss reported for 2024. The wider loss was primarily attributed to non-cash fair value adjustments to financial instruments and interest expenses.

More pressing is the company's cash position. With $13.0 million in cash, cash equivalents, and short-term investments as of December 31, 2025, CalciMedica projects it has enough capital to fund operations only into the fourth quarter of 2026. This runway is short for a company on the verge of initiating a costly pivotal trial program. To advance Auxora through late-stage development and continue progressing CM5480, securing substantial additional financing in the near future will be imperative. The company's ability to leverage its positive AP data and the validation of its CRAC channel platform will be crucial in attracting the necessary investment to continue its mission.